Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy

作者
Meiko Nishimura,Takayuki Kobayashi,Yosuke Aoyama,Saori Kawai,Jun Masuda,Yukinori Ozaki,Mari Hosonaga,Ippei Fukada,Tetsuyo Maeda,Nami Yamashita,Tomo Osako,Toshimi Takano,Takayuki Ueno
出处
期刊:Breast disease [IOS Press]
卷期号:44: 15581551251403784-15581551251403784
标识
DOI:10.1177/15581551251403784
摘要

Background Trastuzumab emtansine (T-DM1) is indicated for HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy (NAC). However, the extent of benefit T-DM1 will provide over trastuzumab plus pertuzumab (HP) in patients with microscopic residual invasive disease after NAC remains unclear. Methods Data of patients with HER2-positive breast cancer who were treated with HER2-targeted therapy as NAC and completed HP or T-DM1 as adjuvant therapy from October 2018 to October 2022 were retrospectively extracted from the institutional database. Invasive disease-free survival (IDFS), overall survival (OS), and safety were analyzed. Results Of the 110 patients, 61 achieved pCR (55.4%), and 49 had residual invasive disease. Of the 49 patients, 29 received HP, and 20 received T-DM1 as adjuvant therapy. The proportion of ypT1aN0 was 31.0% ( n = 9/29) in the HP group and 45.0% ( n = 9/20) in the T-DM1 group. The 3-year IDFS and OS were 96.6% and 95.0%, and 96.6% and 100% in the HP and T-DM1 groups, respectively. The 3-year IDFS and OS of patients with ypT1aN0 were 100% in both groups. The most common adverse events of any grade in the T-DM1 group were aspartate aminotransferase increased (90%) and alanine aminotransferase increased (85%) aminotransferase and platelet count decreased (70%). Conclusion The 3-year IDFS and OS of patients with ypT1aN0 disease who received HP or T-DM1 as adjuvant therapy were comparable.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
没袋鼠完成签到,获得积分10
1秒前
1秒前
寒耒发布了新的文献求助10
1秒前
靓丽醉蝶的应助被健壮的蓝天采纳,获得10
2秒前
luwa的应助被Brian_Hu_采纳,获得10
2秒前
雪白的老二完成签到,获得积分10
3秒前
Mu发布了新的文献求助10
4秒前
4秒前
思源的应助被富贵儿采纳,获得10
4秒前
5秒前
7秒前
7秒前
lll发布了新的文献求助30
7秒前
8秒前
优美的梦之完成签到 ,获得积分10
8秒前
FashionBoy的应助被chen采纳,获得10
8秒前
柳慧发布了新的文献求助10
8秒前
GingerF的应助被小星星采纳,获得100
8秒前
宫立辉完成签到,获得积分10
9秒前
yyyyy发布了新的文献求助10
11秒前
pgojpogk发布了新的文献求助10
11秒前
12秒前
千寒发布了新的文献求助10
12秒前
好运来完成签到,获得积分20
12秒前
zizhu发布了新的文献求助10
13秒前
Mi完成签到,获得积分10
13秒前
14秒前
希望天下0贩的0的应助被yk采纳,获得10
15秒前
一团小煤球完成签到,获得积分10
15秒前
科研通AI6.2的应助被zhailingyou采纳,获得10
17秒前
蓝天的应助被欣慰的冰萍采纳,获得10
17秒前
疯狂的雯子完成签到,获得积分10
18秒前
小二郎的应助被wangyi采纳,获得10
18秒前
Hou完成签到,获得积分10
18秒前
鸡鱼蚝发布了新的文献求助10
18秒前
千寒完成签到,获得积分10
18秒前
19秒前
20秒前
柳慧完成签到,获得积分10
20秒前
KennyBiao完成签到,获得积分10
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Handbook of Pharmaceutical Excipients. 9th ed 400
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
Breaking the World 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153668
求助须知:如何正确求助?哪些是违规求助? 9550448
关于积分的说明 21698499
捐赠科研通 7742484
什么是DOI,文献DOI怎么找? 3425564
关于科研通互助平台的介绍 2550698
邀请新用户注册赠送积分活动 2469211